Online Purchasing Account You are logged on as Guest. LoginRegister a New AccountShopping cart (Empty)
United States 

GSK-3β polyclonal antibody

ADI-KAP-ST002-C 25 µg 175.00 USD
ADI-KAP-ST002-E 100 µg 378.00 USD
Do you need bulk/larger quantities?

Product Details

Alternative Name:Glycogen synthase kinase-3β
Immunogen:Synthetic peptide corresponding to a portion of rat GSK-3β. The sequence is completely conserved in human.
UniProt ID:P18266
GenBank ID:X53428
Source:Purified from rabbit serum.
Species reactivity:Human, Mouse, Rat
Applications:ICC, IHC (PS), WB
Recommended Dilutions/Conditions:Western Blot (1:1,000, colorimetric)
Suggested dilutions/conditions may not be available for all applications.
Optimal conditions must be determined individually for each application.
Application Notes:Detects a band of ~47kDa by Western blot.
Purity Detail:Protein A affinity purified.
Formulation:Liquid. In PBS, pH 7.2, containing 50% glycerol and 0.09% sodium azide.
Handling:Avoid freeze/thaw cycles.
Shipping:Blue Ice
Long Term Storage:-20°C
Scientific Background:Glycogen Synthase Kinase 3β (GSK-3β) is a unique serine/threonine kinase that is inactivated by phosphorylation. In response to insulin binding, PKB/AKT phosphorylates GSK-3β on serine 9, which prevents GSK-3β from phosphorylating glycogen synthase. Unphosphorylated glycogen synthase is active and able to synthesize glycogen. GSK-3β is also unique in that it requires a substrate that has been phosphorylated by a distinct kinase before it can phosphorylate the substrate. This phosphate priming mechanism explains why phosphorylation of serine 9 inactivates GSK-3β. The phosphorylated serine binds to the GSK-3β priming phosphate position and prevents binding of alternative substrates. In addition to insulin signaling, GSK-3β participates in the Wnt signaling pathway, where it forms a complex with axin, beta-catenin and adenomatous polyposis coli (APC) protein. In the presence of Wnts, GSK-3β is unable to phosphorylate beta-catenin, which leads to stabilization of beta-catenin. The Wnt pathway inactivates GSK-3β via the proteins, Dishevelled and FRAT, which disrupt the interaction of GSK-3β with axin, beta-catenin, and APC. Clinically, there is considerable interest in GSK-3β inhibitors because they may mimic the effect of insulin or reduce the hyperphosphorylation of Tau that is observed in Alzheimer's Disease.
Regulatory Status:RUO - Research Use Only
GSK-3β polyclonal antibody Western blot
Western blot analysis of human HeLa (heat shocked) cell lysate, probed with GSK3-β pAb
GSK-3β polyclonal antibody Immunohistochemistry
Immunohistochemistry analysis of human skeletal muscle tissue stained with GSK-3β, pAb at 10µg/ml.
Please mouse over
GSK-3β polyclonal antibody Western blot GSK-3β polyclonal antibody Immunohistochemistry

Related Literature

Integrated solutions for screening Wnt regulators
Integrated solutions for screening Wnt regulators
Download as PDF

Stem Cells
Stem Cells
Download as PDF

Download as PDF

All new literature pieces